The myelodysplastic syndrome(s): a perspective and review highlighting current controversies.
about
Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q).Cyclosporine-responsive thrombocytopenia in a patient with chloramphenicol-associated myelodysplastic syndrome.Health care utilization and mortality among elderly patients with myelodysplastic syndromes.Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes.Epigenetic changes in the myelodysplastic syndrome.NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia.Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia.Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced diseaseAltered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndromeReduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.Classification, treatment goals, and management principles for myelodysplastic syndromes.Gene expression profiling in the myelodysplastic syndromes.Complete Remission of del(5q) Myelodysplastic Syndrome after 7 Days of Lenalidomide Therapy Gives an Alert!A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndromeNUP98-HOX translocations lead to myelodysplastic syndrome in mice and menMyelodysplastic syndromes, aging, and age: correlations, common mechanisms, and clinical implications.Changing the treatment paradigm in myelodysplastic syndromes.Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signalingCytogenetic abnormalities in myelodysplastic syndrome: an overview.Review of therapeutic options and the management of patients with myelodysplastic syndromes.The implication of identifying JAK2 ( V617F ) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis.Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C.Bloodstream infections in internal medicine.An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614).Establishment of a xenograft model of human myelodysplastic syndromesSerum erythropoietin at diagnosis in low grade myelodysplastic syndrome correlates with both red cell zinc protoporphyrin and serum lactic dehydrogenase (LDH) and may reflect severity of ineffective erythropoiesis.Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms.Aberration of p73 promoter methylation in de novo myelodysplastic syndrome.Inositide-specific phospholipase c beta1 gene deletion is a rare event in myelodysplastic syndromes.A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome.Dysplasia and disorder of cell membrane entirety in iron-deficiency anemia.Mutation in RAP1 is a rare event in myelodysplastic syndromes.Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technologyContemporaneous appearance, 18 years after allogeneic bone marrow transplantation, of myelodysplastic syndrome in the patient and the donor
P2860
Q30987570-1E11B525-86D6-4F6F-A7FC-79020BB7AC96Q33370159-845BAFC3-E106-47A3-BB3D-90D09365805BQ33392602-3266A57A-67A2-4BFC-B38C-50E68C543A6EQ33401001-C41EFE45-9DEA-4A89-92B5-39DBE0639A5DQ33431466-99B33E99-4CC7-40B3-9845-7A6786B6C161Q33767309-02C195DA-A3C5-4F4A-BDBB-D2A39CA238E3Q33947406-2037F3D3-BDFB-4CDF-A124-3D6312248D93Q35124582-53E2E3E7-251F-4FB0-B2B4-30021EC37B09Q35611709-02DE4C94-75E1-47C8-86F1-480CC59A74EBQ35657367-ADDC290D-B763-4815-B28E-CE13CA921F2CQ35828771-F8919D38-B847-4313-BC0E-C671250FE462Q35848032-EFE33538-9187-4455-8B6C-5F27564DF989Q35996497-92074BC9-A880-4132-A8F2-7B2E540B6B12Q36221521-488F2EAC-F48F-42CE-8B6D-87B43CE89EFAQ36422512-1B9ED873-D222-48E5-8CD4-46BE25B92E66Q36689145-F0877BA5-B46E-497A-B8F1-274857C9FB31Q36841302-E787CCC1-98CB-413B-8456-DBBB2F2CCE28Q36961721-7B447DF0-9B6F-447D-A9C0-9E1C51C45024Q37277994-94E68636-CA6D-4A5C-9E37-04E2C5EE3872Q37607838-3E9252E8-301B-435F-8A6C-C28245A726A5Q37888830-D71F4AF6-89C1-4BC8-B8D0-927F5383D733Q38095121-D61DFB8E-ED2C-4477-8F5D-58B4C3862FFEQ38420427-C26F3FE7-8170-4E0B-9206-C8925B9A4C96Q38507121-B3A3CB35-46F5-464C-A470-7598364E0D62Q38655657-DA217453-043A-49D7-857F-88BE66253BA7Q38694666-12C01CF4-069C-498D-8DEC-ED2C2F080F10Q41101447-69BFAD60-B77F-4864-AC7C-BAE6B361768FQ42708649-AB64A1BD-0D9D-4644-87C6-1009B79603D1Q46050808-76BD43DE-1DAD-4B18-A7D7-53DB76B77101Q46110570-D91E3D17-9AE5-4166-A385-98F9F5F63238Q46417608-F94FF0FF-663E-42BD-9B23-CB8214B9123DQ46902741-6D0CF65B-13E7-4C46-9714-5E3075E63992Q50526914-1A935C03-956F-4859-BCB5-C52C2410B573Q50637147-9E7AA611-A3A1-4A7C-84E2-363BDBBE818AQ54647172-13247C20-4FC9-4191-A7E6-B582074B5465Q57635516-44167281-0532-4A36-9EA4-0FD66A966A08Q59281275-D4B2CCDB-5CF1-4ECD-A9B4-EEA4BA35F5AB
P2860
The myelodysplastic syndrome(s): a perspective and review highlighting current controversies.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The myelodysplastic syndrome(s ...... ighting current controversies.
@en
type
label
The myelodysplastic syndrome(s ...... ighting current controversies.
@en
prefLabel
The myelodysplastic syndrome(s ...... ighting current controversies.
@en
P1433
P1476
The myelodysplastic syndrome(s ...... ighting current controversies.
@en
P2093
David P Steensma
P304
P356
10.1016/S0145-2126(02)00098-X
P577
2003-02-01T00:00:00Z